Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
(World News USA)

Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia - Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation - - All nine evaluable patients with RAS wild-type achieved stable disease or better - - Preliminary data presented today at American Society of Hematology Annual Meeting - - More data, including progression-free survival in the RAS wild-type and RAS mutant subsets, expected in 2018 - SAN DIEGO, Dec. 10, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the...